Table 1

Summary statistics for baseline characteristics before propensity score adjustment

Rituximab (n=575)TNF antagonists (n=513)p Value
Female, N (%)472 (82.0)413 (80.5)0.400
Age, mean (SD)55.3 (12.8)54.5 (13.5)0.364
>5 years since diagnosis, N (%)430 (79.3)327 (67.4)<0.0001
Extra-articular manifestations, N (%)187 (36.7)111 (27.7)<0.0001
Prior no of TNFs >1, N (%)208 (37.0)58 (11.4)<0.0001
Use of ≥2 DMARDs, N (%)397 (92.7)415 (86.6)0.0028
Toxicity DMARDs, N (%)164 (38.7)132 (27.8)0.0005
Rheumatoid factor ≥60, N (%)223 (54.3)177 (56.3)0.595
DAS28, mean (SD)5.5 (1.20)5.0 (1.30)<0.0001
  • Only patients with sufficient data for analysis are included in the table.

  • DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drug; TNF, tumour necrosis factor.